Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
Go back to Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas| (NASDAQ: ARVN) | Delayed: 9.41 +0.09 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.32 | 52 Week High | $ | |||
| Open | $9.27 | 52 Week Low | $ | |||
| Day High | $9.43 | P/E | N/A | |||
| Day Low | $9.15 | EPS | $ | |||
| Volume | 187,922 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.13 -0.17 (0.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.30 | 52 Week High | $37.39 | |||
| Open | $27.97 | 52 Week Low | $28.25 | |||
| Day High | $28.17 | P/E | 17.05 | |||
| Day Low | $27.83 | EPS | $1.65 | |||
| Volume | 11,815,622 | |||||

